View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job


Tox 21 and New Approach Methodology (NAMs): Using Emerging Technologies to Improve Translational Research and Safety Assessment Predictions (jointly by SOT-NorCal & PBSS)

Speakers: Kathryn Page (Clorox); Shichang Miao (ChemoCentryx); Thomas Hartung (The Bloomberg School of Public Health); Emily Reinke (U.S. Army Public Health Center); Suzanne Fitzpatrick (FDA); Pamela Lein (UC Davis); Ellen Berg (Eurofins); Will Proctor (Genentech)
Date: 2019-04-25
Time: 8:30-17:00 Pacific Time
Registration fee: (USD): Regular (with lunch): $60; Students & Postdocs (with lunch): $0
Location: South San Francisco Conference Center
Major Sponsor:
Vendor show vendors registered to date:
Registration deadline:2019-04-23  (it will close sooner if the seating cap is reached)

About the Topic

Preliminary Agenda

Morning Session

7:30 am – 8:30 am          Registration & Breakfast

8:30 am – 8:45 am          Opening message from The NorCal & PBSS Presidents - Kathryn Page, PhD, DABT, Clorox; Shichang Miao, PhD, ChemoCentryx

8:45 am – 9:30 am          Plenary Speaker:  Alternative Methods for the 21st Century - Thomas Hartung, PhD, Johns Hopkins Bloomberg School of Public Health

9:30 am – 10:15 am        From Experimental Concept to Regulatory Acceptance:  The Success of Alternative Methods in Skin Sensitization Testing - Emily Reinke, PhD, DABT, U.S. Army Public Health Center

10:15 am – 10:30 am     Coffee Break

10:30 am – 11:15 am     Consumer Product Safety Assessment: An Alternative Approach - Kathryn Page, PhD, DABT, Clorox

11:15 am – 12:00 pm     Predictive Toxicology for Regulatory Decisions:  Implementing New Approaches at FDA - Suzanne Fitzpatrick, PhD, FDA

12:00 pm – 1:30 pm       Lunch Break: Lunch with Experts, Posters

Afternoon Session

1:30 pm – 1:45 pm         Chapter announcements and acknowledgements

1:45 am – 2:05 am          NorCal Student Award presentation: TBD

2:05 pm – 2:45 pm         In Vitro and Alternative Models of Neurotoxicity:  Opportunities and Challenges for Neurotoxicity Testing - Pamela Lein, PhD, DABT, UC Davis

2:45 pm – 3:00 pm         Coffee Break

3:00 pm – 3:45 pm         Applying Human-based Phenotypic Profiling in Early Drug Discovery - Ellen Berg, PhD, Eurofins

3:45 pm – 4:30 pm         Industry Perspective on Evaluating, Qualifying, and Implementing Complex In Vitro Models to Support Drug Discovery - Will Proctor, PhD, DABT, Genentech

4:30 pm – 6:00 pm         Reception & Networking

2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
┬ęPharmaceutical & BioScience Society, International; Last Modified: 4/14/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Submit a Text Ad